A prospective comparison of the two main indications of efavirenz in 2001 highly active antiretroviral therapy (HAART) regimens: First-line versus salvage use

Journal of Antimicrobial Chemotherapy

Volumn 49, Issue 5, 2002, Pages 723-729

  Manfredi, Roberto ^a   Calza, Leonardo ^a   Chiodo, Francesco ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Antiretroviral resistance; Efavirenz; Efficacy; First line treatment; Highly active antiretroviral therapy; Salvage regimen

Indexed keywords

ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR; NELFINAVIR; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; OXAZINE DERIVATIVE; VIRUS DNA;

ANAMNESIS; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS RESISTANCE; DOSE RESPONSE; DRUG EFFICACY; DRUG EXPOSURE; DRUG INDICATION; DRUG RESPONSE; DRUG TOLERABILITY; DRUG USE; FOLLOW UP; GENE IDENTIFICATION; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MENTAL DISEASE; NEUROLOGIC DISEASE; PROSPECTIVE STUDY; SALVAGE THERAPY; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS GENE; VIRUS RESISTANCE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COMPARATIVE STUDY; GENETICS; IMMUNOLOGY; METHODOLOGY; VIROLOGY;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DNA, VIRAL; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; OXAZINES; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 0036001166     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkf030     Document Type: Article

References (31)

1. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. The INCAS Trial
2. A randomized, double-blind trial on the use of a triple combination including nevirapine, a non-nucleoside reverse transcriptase inhibitor, in antiretroviral naïve patients with advanced disease
3. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse transcriptase inhibitors in children infected with human immunodeficiency virus type 1
4. Efavirenz plus zidovudine and lamivudine, efevirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
5. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine
6. Clinical uses of non-nucleoside reverse transcriptase inhibitors
7. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy
8. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society - USA Panel
9. Antiretroviral therapy for previously treated patients
10. Salvage antiretroviral therapy
11. Quantification of the impact of HIV-1 reverse transcriptase and protease mutations on the efficacy of rescue HAART
12. The effect of nevirapine in combination with nelfinavir in heavily pretreated HIV-1-infected patients: A prospective, open-label, controlled, randomized study
13. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
14. Efavirenz: Resistance and cross-resistance
15. Genotypic and phenotypic nevirapine resistance correlates with failure during salvage therapy including abacavir and nevirapine
16. Non-nucleoside reverse transcriptase inhibitor failure impairs HIV-RNA responses to efavirenz-containing salvage antiretroviral therapy
17. Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen
18. Efavirenz- and adefovir-dipivoxil-based salvage therapy in highly treatment-experienced patients: Clinical and genotypic predictors of virologic response
19. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor in heavily pre-treated HIV-infected patients
20. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection
21. Determinants of virological response to antiretroviral therapy: Implications for long-term strategies
22. Clinical utility of testing human immunodeficiency virus for drug resistance
23. Pattern of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy
24. High prevalence of genotypic and phenotypic HIV-1-drug-resistant strains among patients receiving antiretroviral therapy in Abdjian, Côte d'Ivoire
25. Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: Impact on virological response to efavirenz-based therapy
26. Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz
27. Clinical and immunological response without decrease in virus load in patients with AIDS after 24 months of highly active antiretroviral therapy
28. + cell response after virological failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection
29. A cross-sectional survey of HIV genotype mutations conferring resistance to all nonnucleoside reverse transcriptase inhibitors and related features, at the time of failure of antiretroviral therapy in the real world
30. Prevalence of multiple dideoxynucleoside analogue resistance (MddNR) in a multicenter cohort of HIV-1-infected Italian patients with virologic failure